CA-XPRIZE
23.6.2021 19:32:08 CEST | Business Wire | Press release
XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, and IBM Watson , IBM’s AI technology for business, today announced the Grand Prize Winner in the $5M IBM Watson AI XPRIZE Challenge . First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges.
Winning first place honors is Zzapp Malaria , in second place is Aifred Health , followed by Marinus Analytics . These finalists were selected out of a pool of 10 semifinalists following presentations of their solutions to a panel of judges during an event held at TED headquarters in New York City last year. A $3 million grand prize, $1 million second place prize, and $500k third place prize will be awarded to the teams. In total, over 150 teams throughout the world joined the competition.
"After five years of hard work and dedication, XPRIZE is thrilled to announce Zzapp Malaria as the grand prize winner of IBM Watson AI XPRIZE,” said Anousheh Ansari, CEO of XPRIZE. “Zzapp Malaria, Aifred Health and Marinus Analytics are on the forefront of AI advancement, and we are looking forward to seeing firsthand the positive impact they will have on our future.”
"Each of the three finalists of the IBM Watson AI XPRIZE showcase what's possible when the power of AI is used to address some of the world’s toughest challenges,” said Daniel Hernandez, General Manager, IBM Data and AI. “It’s inspiring to witness how the AI technologies we developed at IBM help these organizations realize and scale their good tech solutions to drive positive societal change.”
Based out of Tel Aviv, Israel, Zzapp Malaria is committed to malaria elimination. The team’s AI technology is geared towards tackling the main challenges faced by malaria elimination campaigns by creating custom models, built with tools like IBM Watson Studio for Cloud Pak for Data, to predict the number of small water bodies caused by weather, enabling it to optimize the timing for launching larviciding operations.
- Marinus Analytics (based out of Pittsburgh, PA): A woman-owned company founded in 2014 out of Carnegie Mellon Robotics that is driven by a single social mission: To fight human trafficking. Their solution, Traffic Jam, is a suite of analytics tools that saves hours and sometimes days of investigative time to find traffickers and recover victims by quickly turning big data into actionable intelligence. Marinus Analytics has used IBM Watson Discovery and IBM Watson Assistant to extend their Traffic Jam application, aiding investigation into financial fraud and the illicit flow of proceeds to international crime groups.
- Aifred Health (based out of Montreal, Canada): A digital health company focused on clinical decision support in mental health, starting with depression. The team’s solution uses AI to learn from thousands of patients to help tailor treatment, reducing the time it takes for a patient to reach remission. IBM Watson Health is providing Aifred Health with millions of records of observational depression data to improve their ML models.
To determine the winner, XPRIZE AI convened a global jury of representatives from around the world. The jury evaluated each team based on their performance in the following four dimensions: achieved technical impact, evidenced real-world impact, scalability of real-world impact, and ethics and safety.
The winning teams were announced today in partnership with WIRED during the IBM Watson AI XPRIZE’s AI For Good fireside chat featuring Anousheh Ansari, CEO of XPRIZE, and Seth Dobrin, IBM’s Chief AI Officer. The two discussed the challenge and the importance of AI for the future of humanity. As part of their partnership with WIRED, XPRIZE opened up a public vote for the Most Inspiring Team, and Zzapp Malaria was selected as the winner. You can watch the full fireside chat and view additional content via WIRED’s content hub linked here.
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100M XPRIZE Carbon Removal, $15M XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE and $5 Million XPRIZE Rapid Reskilling. For more information, visit xprize.org.
About IBM Watson
Watson is IBM’s AI technology for business, helping organizations to better predict and shape future outcomes, automate complex processes, and optimize employees’ time. Watson has evolved from an IBM Research project, to experimentation, to a scaled, open set of products that run anywhere. With more than 40,000 client engagements, Watson is being applied by leading global brands across a variety of industries to transform how people work. To learn more, visit: https://www.ibm.com/watson .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005848/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom